Filing Details
- Accession Number:
- 0000905148-18-000454
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-04-19 16:20:04
- Reporting Period:
- 2018-04-17
- Accepted Time:
- 2018-04-19 16:20:04
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
926617 | Vermillion Inc. | VRML | In Vitro & In Vivo Diagnostic Substances (2835) | 330595156 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1021412 | W Jack Schuler | 100 N. Field Drive Suite 360 Lake Forest IL 60045 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.001 | Acquisiton | 2018-04-17 | 2,838,090 | $1.00 | 13,416,342 | No | 4 | P | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series B Convertible Preferred Stock (Right to Buy) | Acquisiton | 2018-04-17 | 39,619 | $100.00 | 3,961,900 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
39,619 | No | 4 | P | Indirect |
Footnotes
- These shares of Common Stock ("Shares") and Series B Convertible Preferred Stock ("Preferred Stock") are directly held by the Jack W. Schuler Living Trust. Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.
- Each share of Preferred Stock is initially convertible into 100 Shares automatically upon the Requisite Stockholder Approval (defined and described further in the Schedule 13D/A filed by the Reporting Person on April 19, 2018), subject to customary anti-dilution adjustments, reflecting an initial conversion price equal to $1.00 per share. The Preferred Stock has no expiration date.